Hydromethylthionine
Small moleculeexperimental
Clinical trial activity
7 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
5
Phase 3
5
Phase 4
0
Earliest trial started Sep 1, 2012 (NCT01626391)
Timeline
Indications
Mechanism of action
- Microtubule-associated protein tauINHIBITOR
MAPT inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CN(C)c1ccc2c(c1)Sc1cc(N(C)C)ccc1N2- Mol. weight
- 285.42 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL549963 ↗
Also known as
- trx0237
- trx0237
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03446001 | Phase 2/Phase 3 (Phase 3) | Jan 10, 2018 | TauRx Therapeutics Ltd |
| NCT02245568 | Phase 3 | Aug 1, 2014 | TauRx Therapeutics Ltd |
| NCT01626378 | Phase 3 | May 1, 2013 | TauRx Therapeutics Ltd |
| NCT01689246 | Phase 3 | Jan 1, 2013 | TauRx Therapeutics Ltd |
| NCT01689233 | Phase 3 | Oct 1, 2012 | TauRx Therapeutics Ltd |
| NCT01626391 | Phase 2 | Sep 1, 2012 | MAC Clinical Research, TauRx Therapeutics Ltd |
| NCT03539380 | N/A | — | TauRx Therapeutics Ltd |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| TauRx Therapeutics Ltd | For profit | 7 | 7 | 3 | 2012 |
| MAC Clinical Research | For profit | 1 | 0 | 1 | 2012 |
2 organizations
Page 1 / 1